Prostate Cancer Foundation VL

Real-World Evaluation of Disparities in Prostate Cancer Outcomes - Daniel Spratt

Daniel Spratt and Todd Morgan discuss the analysis of why is it that black men appear to be dying more often of prostate cancer. They review their approach to understanding more about this real-world question. Biographies: Todd Matthew Morgan MD Associate Professor Specialties: Urology Area of Practice: Prostate Cancer, including robotic prostatectomy and active surveillance; Bladder Cancer, inclu...

Sharing Clinical Information through Social Media - Todd Morgan & Dan Spratt

Dan Spratt, MD and Todd Morgan, MD discuss the role of social media in medical and scientific communication with Charles Ryan, MD. All three agree that social media, especially Twitter, helps to provide quicker access to breaking information at congresses when it is not possible to attend the live meeting. This communication outlet also typically provides more expert opinion and commentary that is...

Precision Oncology: The PCF - Veterans Affairs (VA) Initiative - Bruce Montgomery

Bruce Montgomery shares an update on the PCF - VA research Initiative on precision oncology in prostate cancer. Prostate Cancer Foundation has provided a $50 million dollar contribution to this VA specific prostate cancer effort. Bruce and Chuck Ryan discuss the developments to date and the future plans. Biographies: Bruce Montgomery, MD Board-certified oncologist, clinical director of Genitourina...

The Next Big Thing in Prostate Cancer: Neal Shore, Alicia Morgans, and Charles Ryan

In this conversation, Neal Shore, Alicia Morgans and Chuck Ryan discuss their views on what the next “big thing” is in prostate cancer and exciting new developments in 2019. These advancements include a renewed look at the patient’s experience and point of view to integrate into treatment decision making. The group sees continued research in race and genetic disparities and how these factors effec...

Alpha Particles as Radiopharmaceuticals in the Treatment of Bone Metastases

Neal Shore and Oliver Sartor discuss the role of both alpha and beta radiopharmaceuticals that are on the horizon for treatment of bone metastases in prostate cancer. Dr. Sartor reviews the compelling data for the use radium-223 with respect to the improvement seen in overall survival along with additional alpha targeted agents that are on the horizon. He also discusses the role of the beta agents...

Improving Natural Killer Cell Immunotherapy for Cancer - Martin Felices

Martin Felices discusses a unique approach to using natural killer (NK) cells to target a variety of cancers. NK cells seek out abnormal cells while also producing inflammatory cytokines that induce the adaptive immune response. There is a known role of NK cells in hematologic malignancies whereas in tumor micro environments the NK cells display characteristics of exhaustion and lack of maturation...

Overall Survival Benefit and Racial Disparities in African American Men with Metastatic Prostate Cancer - Oliver Sartor

Neal Shore and Oliver Sartor cover the topic of racial disparities in prostate cancer and the use of immunotherapy particularly sipuleucel-T in the African American community. Oliver does a deep dive into the double-blind, placebo-controlled, multicenter trial, Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) study, involving 512 men with metastatic castration-resistant prostate cancer...

Role of PARP Inhibitors in Prostate Cancer - Evan Yu

Neal Shore and Evan Yu share in discussion on the evolving role of PARP inhibitors in the treatment of mCRPC. Dr. Yu reviews the early interim results of rucaparib in the TRITON-2 study and points out the intricacies that must be considered when evaluating all the recent data involving DNA mutations. Drs. Shore and Yu discuss the class of PARP inhibitors in clinical development and what makes each...

Effectiveness and Resistance to PSMA Targeted RadioLigand Therapy using 177 Lu-PSMA-617 - Jeremie Calais

Jeremie Calais discusses his PCF funded research on 177 Lu-PSMA-617 with respect to resistance patterns that develop to treatment along with primary resistance. Drs. Calais and Ryan discuss patient and tumor characteristics for both those demonstrating effectiveness to therapy and those that develop resistance or have primary resistance. Biographies: Jeremie Calais, MD, MSc Assistant Professor at...

Integrating Social Media as an Effective Teaching Tool for Patients - Stacy Loeb

Stacy Loeb discusses with Alicia Morgans her successful implementation of a Twitter-based prostate cancer journal club for patients that was implemented in 2017, under #prostatejc. They also discuss the necessity to vet the quality of information available to consumers. Stacy refers to a content analysis of YouTube videos related to prostate cancer, published in 2017 in the American Journal of Men...

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.